Literature DB >> 18667380

Pancreatic neuroendocrine tumours.

J Ruiz-Tovar1, P Priego, E Martínez-Molina, V Morales, A Sanjuanbenito, E Lobo.   

Abstract

INTRODUCTION: Pancreatic neuroendocrine tumours (PNT) are infrequent epithelial neoplasms associated with a better outcome than pancreatic adenocarcinoma.
MATERIALS AND METHODS: We analysed our 22 years of experience in managing PNT. Forty-nine patients (27 women and 22 men) with a mean age of 49 years were studied. There were 28 insulinomas, eight glucagonomas, three gastrinomas, one VIPoma and one carcinoid. Eight patients presented with nonfunctional tumours. Enucleation was performed in 20 patients, distal pancreatectomy in 16, middle pancreatic resection in four, cephalic pancreatoduodenectomy in two and total pancreatoduodenectomy in one. In six patients, the tumour was not resected.
RESULTS: Postoperative complication rate was 22%: six pancreatic fistulas, three intra-abdominal collections, one remnant pancreatitis and one pancreatic pseudocyst. There was no mortality. 39 cases showed benign histologic features and ten malignant ones. Symptomatic palliation was achieved in 94% of the cases. Five patients presented recurrences: three liver metastases and two pancreatic recurrences. Actuarial mean survival was 163 months and was longer in insulinomas, in those tumours completely resected and in tumours with benign histological features.
CONCLUSION: Conservative surgery of the pancreas is preferred, but aggressive surgery is indicated when the primary tumour can be controlled. Despite of minimising pancreatic resection, there is a high complication rate, mainly pancreatic fistulas, though they can often be conservatively managed. Insulinomas are the PNT with better outcome; those completely resected also associate a better prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 18667380     DOI: 10.1007/s12094-008-0238-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  9 in total

1.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  Metastatic neuroendocrine hepatic tumors: resection improves survival.

Authors:  Sandeepa Musunuru; Herbert Chen; Sharad Rajpal; Nicholas Stephani; John C McDermott; Kyle Holen; Layton F Rikkers; Sharon M Weber
Journal:  Arch Surg       Date:  2006-10

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients.

Authors:  C C Solorzano; J E Lee; P W Pisters; J N Vauthey; G D Ayers; M E Jean; R F Gagel; J A Ajani; R A Wolff; D B Evans
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

Review 5.  Neuroendocrine tumors of the pancreas and duodenum.

Authors:  J A Norton
Journal:  Curr Probl Surg       Date:  1994-02       Impact factor: 1.909

6.  Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?

Authors:  Swee H Teh; Clifford Deveney; Brett C Sheppard
Journal:  Am J Surg       Date:  2007-05       Impact factor: 2.565

7.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

8.  Is there a prognostic difference between functional and nonfunctional islet cell tumors?

Authors:  T J White; J A Edney; J S Thompson; F W Karrer; B J Moor
Journal:  Am J Surg       Date:  1994-12       Impact factor: 2.565

9.  [Diagnosis and treatment of pancreatic insulinoma].

Authors:  P Priego; A Sanjuanbenito; E Martínez Molina; E Lobo; D García Teruel; V Morales; G Rodríguez; V Fresneda
Journal:  Rev Esp Enferm Dig       Date:  2007-04       Impact factor: 2.086

  9 in total
  4 in total

Review 1.  Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection.

Authors:  Paige Finkelstein; Rishika Sharma; Omar Picado; Rahul Gadde; Heather Stuart; Caroline Ripat; Alan S Livingstone; Danny Sleeman; Nipun Merchant; Danny Yakoub
Journal:  J Gastrointest Surg       Date:  2017-03-02       Impact factor: 3.452

2.  Zollinger-Ellison Syndrome in a 12-year-old Child.

Authors:  Abir Lal Nath; Nandita A Saxena; Bharati K Kulkarni; Shyam S Borwankar; Hemant N Lahoti; Sanjay N Oak
Journal:  J Indian Assoc Pediatr Surg       Date:  2017 Jul-Sep

Review 3.  Zollinger-Ellison Syndrome Associated with von Recklinghausen Disease: Case Report and Literature Review.

Authors:  Mohamad J Alshikho; Salem I Noureldine; Joud M Talas; Antoine Nasimian; Safi Zazou; Bashir Mobaed; Mahmoud Nasser
Journal:  Am J Case Rep       Date:  2016-06-13

Review 4.  Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review.

Authors:  Anneke P J Jilesen; Casper H J van Eijck; K H in't Hof; S van Dieren; Dirk J Gouma; Els J M Nieveen van Dijkum
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.